Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities by Prathibha Reddy Gajjala et al.
REVIEW
published: 08 July 2015
doi: 10.3389/fimmu.2015.00340
Edited by:
Mario Mellado,
Consejo Superior de Investigaciones
Científicas, Spain
Reviewed by:
Herminia González-Navarro,
INCLIVA, Spain
Guadalupe Sabio,
CNIC, Spain
*Correspondence:
Joachim Jankowski,
Institute of Molecular Cardiovascular
Research, RWTH University of
Aachen, Pauwelsstrasse 30, Aachen
D-52074, Germany
jjankowski@ukaachen.de
Specialty section:
This article was submitted to
Chemoattractants, a section of the
journal Frontiers in Immunology
Received: 06 May 2015
Accepted: 17 June 2015
Published: 08 July 2015
Citation:
Gajjala PR, Sanati M and
Jankowski J (2015) Cellular and
molecular mechanisms of chronic
kidney disease with diabetes mellitus
and cardiovascular diseases as
its comorbidities.
Front. Immunol. 6:340.
doi: 10.3389/fimmu.2015.00340
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diabetes mellitus and cardiovascular
diseases as its comorbidities
Prathibha Reddy Gajjala, Maryam Sanati and Joachim Jankowski*
Institute for Molecular Cardiovascular Research, Universitätsklinikum RWTH Aachen, Aachen, Germany
Chronic kidney disease (CKD), diabetes mellitus (DM), and cardiovascular diseases (CVD)
are complex disorders of partly unknown genesis and mostly known progression factors.
CVD and DM are the risk factors of CKD and are strongly intertwined since DM can lead
to both CKD and/or CVD, and CVD can lead to kidney disease. In recent years, our
knowledge of CKD, DM, and CVD has been expanded and several important experimen-
tal, clinical, and epidemiological associations have been reported. The tight cellular and
molecular interactions between the renal, diabetic, and cardiovascular systems in acute
or chronic disease settings are becoming increasingly evident. However, the (patho-)
physiological basis of the interactions of CKD, DM, and CVD with involvement of multiple
endogenous and environmental factors is highly complex and our knowledge is still at its
infancy. Not only single pathways and mediators of progression of these diseases have
to be considered in these processes but also the mutual interactions of these factors are
essential. The recent advances in proteomics and integrative analysis technologies have
allowed rapid progress in analyzing complex disorders and clearly show the opportunity
for new efficient and specific therapies. More than a dozen pathways have been identified
so far, including hyperactivity of the renin–angiotensin (RAS)–aldosterone system, osmotic
sodium retention, endothelial dysfunction, dyslipidemia, RAS/RAF/extracellular-signal-
regulated kinase pathway, modification of the purinergic system, phosphatidylinositol 3-
kinase (PI 3-kinase)-dependent signaling pathways, and inflammation, all leading to histo-
morphological alterations of the kidney and vessels of diabetic and non-diabetic patients.
Since a better understanding of the common cellular and molecular mechanisms of these
diseases may be a key to successful identification of new therapeutic targets, we review
in this paper the current literature about cellular and molecular mechanisms of CKD.
Keywords: cardiovascular diseases, diabetes mellitus, inflammation, fibrosis, chronic kidney diseases
Introduction
A healthy person could be defined as “a man with highly/tightly regulated and coordinated complex
biological networks.” The crosstalk between the organs and the systems via molecular, cellular,
paracrine, endocrine, and neuronal factors are essential in regulating these networks (1). However,
this tight–knit relationship is deregulated at some point when your body goes through a disease or
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disorder, which in turn influences the function of other organs
and the challenge is to find the right target for that specific
pathway (2). One example is the crosstalk between the pancreas,
heart, and kidney organs, leading to vascular and renal diseases
as well as diabetic mellitus (DM), which are strongly entwined
with each other. Although, many mediators and pathways have
been reported in the literature in regard to these diseases, their
genesis is still a puzzle (3, 4). In this paper, we reviewed the current
incidence, pathways, and the mediators involved in these intricate
diseases and made an attempt to compel the common risk factors
from the current literature.
Current Status on Incidence and
Prevalence of CKD, DM, and CVD
Since two decades, the shift in the mortality and morbidity is
being increased from infectious diseases to non-communicable
disease worldwide (5). This rise in the number of patients mostly
reflects to vascular and renal disease as well as DM, which are the
major public health problem both in developed and developing
countries, imposing burden on economy (6).
Chronic Kidney Disease
It is defined as a change in the kidney function or structure for
more than 3months that affects the health of an individual irre-
spective of the cause (7). Based on the glomerular filtration rate
(GFR) and albuminuria content it is set into five stages. Accord-
ing to KDIGO guidelines people with GFR 90ml/min/1.73m2
are categorized into first stage where the kidney functions nor-
mally, 60–89ml/min/1.73m2 falls in the second stage with mildly
decreased function. The third stage is sub divided into two;
people with 45–59ml/min/1.73m2 and 30–44ml/min/1.73m2,
where the GFR is mildly to severely decreased. In stage 4, the
GFR decreases to 15–29ml/min/1.73m2 and in the fifth stage
(<15ml/min/1.73m2), kidney fails to function. The early stages
are asymptomatic and the end-stage is treated by dialysis or
transplantation (8). Diabetes, hypertension, cardiovascular dis-
eases (CVD), and cigarette smoking are the common risk fac-
tors of chronic kidney disease (CKD) (9, 10). CKD arises due
to many pathological insults that affects the renal function and
destroys some of the nephrons. As a result, the other nephrons
compensate the function of injured nephrons by hyper filtration.
Over a period of time, it develops glomerular hypertension, pro-
teinuria, and eventually loss of renal function (11). An increase
in the glomerular capillary pressure leads to the destruction of
glomerular capillary wall leading to the dysfunction of podocytes
that covers the capillaries and allow the permeability of macro-
molecules (12). These series of insults result in the release of
inflammatory mediators and stimulate the proliferation of cells
involved in fibrosis. Protenuria impairs the reparative mecha-
nisms resulting in the scar formation due to the accumulation
of extracellular matrix (ECM) molecules finally leading to renal
failure.
Incidence and Prevalence
The incidence of CKD is not clearly known since a large number
of patients die due to cardiovascular disease before they progress
to end-stage renal disease. In Europe and North America, the
prevalence was found to be ~10% and in the US, the preva-
lence was found to be 13.1% (13). Zhang et al. (14) reviewed 26
population-based studies conducted on the prevalence of CKD
and reported that in the elderly, the prevalence was between 23.4
and 35.8%. Ameta-analysis by Nitsch et al. studied the association
of GFR, albuminuria with mortality, and renal failure by sex, and
observed that the increased risk of CKD is equal between both
sexes (15).
Diabetes Mellitus
Diabetes mellitus is a group of metabolic disorders resulting from
hyperglycemia caused by genetic, molecular, or biochemical fac-
tors and activation of renin–angiotensin system (RAS), which
eventually leads to the damage of end-organs like kidney (16).Dia-
betic nephropathy (DN), caused by DM, is one of the progressive
kidney diseases characterized by damaged vessels (angiopathy)
due to type 1 or type 2 diabetes, hypertension, or dyslipidemia
affecting kidney filtering system that might progress to end-stage
chronic kidney disease (CKD) (17). DN is also associated with
CVD increasing mortality of DM patients (18). The hallmarks of
DN are the abnormalities in the glomerulus that alter the structure
of podocytes, the decrease in nephrin expression, and the thick-
ening of basement, tubular, and glomerular membranes by the
extracellular deposition causing tubulointerstitial and glomerular
fibrosis (18).
Incidence and Prevalence
According to 2014 statistics, 387million people are suffering from
DMand the prevalence is around 8.3%worldwide, NorthAmerica
being on top (11.4%). 4.9 million deaths were reported in the year
2014 and 46.3% people are undiagnosed (19). DMaccounts for 4%
of global deaths below the age of 70 years (20). About 25–40% of
diabetic patients suffer from DN and/or some degree of CKD (17,
21).
Cardiovascular Disease
Cardiovascular diseases is a group of disorders that is associ-
ated with the circulatory system including coronary heart dis-
ease (CHD), cerebrovascular disease, peripheral arterial disease,
rheumatic heart disease, congenital heart disease, cardiomy-
opathies, cardiac arrhythmias, and deep vein thrombosis and
pulmonary embolism (22). The major risk factors associated with
CVD are hypertension, hypercholesterolemia, dyslipidemia, dia-
betes, smoking, physical inactivity, and obesity (23). Although,
few studies have shown that the decrease in the kidney function
and higher albuminuria are independent risk factors and not
related to diabetes and hypertension (24, 25).
Incidence and Prevalence
It is estimated that more than 17 million deaths were reported
in the year 2012 globally, which accounts for 31% of all deaths
and might increase to 23.3 million by the year 2030. Among these
deaths, 7.4 million deaths were due to CHD and the rest were
due to stroke, mostly observed in low-income andmiddle-income
countries (22).
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Key Cellular and Molecular Events
RAAS System
One of the key players that have been implicated in the patho-
genesis of cardiorenal disease is renin–angiotensin–aldosterone
system (RAAS). In response to the decrease in the renal perfusion
pressure, renin (protease) is produced by the juxtaglomerular cells
of the kidney. It acts on an inactive peptide called angiotensinogen
produced by the liver, converting it to angiotensin-I, which is
a rate limiting and initial step of RAAS (26). Apart from jux-
taglomerular cells, the highest expression of renin (Prorenin) is
observed in the connecting tubules and collecting ducts in dia-
betes patients (27). Angiotensin-I is catalyzed into octapeptides
by angiotensin converting enzyme (ACE-dipeptidyl carboxypep-
tidase), produced in the lungs and lymphocytes (28), to form
angiotensin II, which is an active peptide (29). Angiotensin II is
also produced by chymase and cathepsin G, which are indepen-
dent of ACE activity (30). Furthermore, angiotensin II is cleaved
to different peptides by the endopeptidases like ACE2. Recently,
many new components have been identified in the RAAS sys-
tem like angioprotectin, Ang III, IV, V, Ang-(1–7), Angiotensin-
A, Alamandine, and their co-factors like vasodilation inducing
factor (VIF) (31–34), They are mainly formed by the action of
several endopeptidase that act via Mas receptors or Mas-related
G-protein-coupled receptor membrane D (MrgD) receptors and
they have shown to have vasodilatory effects (33, 35). The effects
of Angiotensin II is mediated by the G-protein coupled receptors,
i.e., angiotensin type 1 (AT1), angiotensin type 2 (AT2) receptors
(30), or the MAS receptor (28). The former being expressed in
several tissues like cardiovascular system, kidney, and the sympa-
thetic nervous system (35), and the latter is expressed during fetal
life and in adults restricted to the adrenals, ovary, brain, heart, and
uterus (36). Angiotensin receptors share overall 30% homology
and as a result they have different functions and are adapted to
different signal transduction pathways (37). Ang II-AT1 axis has
a role in vasoconstriction, cell proliferation, and oxidative stress
in the kidney and is counteracted by AT2 receptor, which pos-
sesses vasodilatory, antiproliferative, and apoptotic properties (38,
39). Activation of AT1 receptors by angiotensin II in the kidney
constricts the efferent arteriole, which results in a decrease of the
blood flow that affects the glomerular filtration by raising the
glomerular capillary pressure. This in turn results in glomerular
injury and an increase in the production of nephrotoxic reactive
oxygen species (ROS), profibrotic cytokines, and growth factors.
The production of these components stimulates mitogenesis of
fibroblast cells that deposit the ECM (renal fibrosis) and inhibits
the turnover, leading to CKD (40, 41). Angioprotectin antago-
nized the contractile actions of Ang II, mediated by theMas recep-
tor, and Ang A has the same affinity to the AT1 receptor as Ang
II, but has higher affinity toward AT2 receptor thusmaymodulate
the harmful effects ofAng II (31, 32). Alamandine acts through the
Mrg receptor and shows its vasodilatory effects (33). Furthermore,
the recently identified factor vasodilation inducing factor (VIF), a
chromogranin peptide, reduces the direct vasoconstrictive effects
of Ang II, independent of NO in human plasma (34).
In adrenal cortex, Ang II stimulates the release of aldosterone
from zona glomerulosa via AT1, which sequentially regulates the
blood pressure, fluid, and electrolyte balance through mineralo-
corticoid receptors of the distal tubule and collecting duct (42).
Aldosterone binds to themineralocorticoid receptor that regulates
the sodium–potassium pumps (43) and since it has cell prolifera-
tive and profibrotic properties, it directly increases the expression
and production of the profibrotic cytokine “transforming growth
factor β” (TGF-β). In kidney disease models, aldosterone synthe-
sis is increased and implicated in the proliferation of fibroblast
cells, renal fibrosis, and induction of hypertension due to the
sodium overload (44). All these effects synergistically provoke
renal damage.
The notion of RAAS acting systemically has been changed by
the discovery of local RAAS with paracrine or autocrine action
during pathogenesis (32, 45), e.g., during hyperglycemia and pro-
teinuria, each component of RAAS was observed in the proximal
tubular cells that synthesize Ang II from angiotensinogen into
interstitial and luminal side, leading to the activation of sodium
pumps besides aldosterone (46, 47). In β cells of pancreas, the
deleterious axis of RAAS, i.e., Ang II-ACE-AT1R-aldosterone
increases the oxidative stress, promotes apoptosis, decreases the
uptake of glucose (by suppressing the GLUT2 through AT1R),
and increases the production of ROS through NADPH oxidase
(NOX), thereby decreasing the production of insulin leading to
hyperglycemia (4). Figure 1 gives the overview of the mediators
in RAAS leading to CKD, DM, and CVD.
Wnt/β-catenin signaling pathway plays an essential role in
the organogenesis and tissue homeostasis, which upon activation
translocate β-catenin into nucleus, that binds to the T-cell factor
(TCF) or lymphoid enhancing factor (LEF) along with other co-
factors like CREB-binding protein (CBP), which eventually tran-
scribes the target genes. In healthy subjects, this pathway is silent
in kidneys, but in CKD, it is reactivated (48). By bioinformatics
approach, Zhou et al. (49) demonstrated that all RAS genes have
putative TCF/LEF binding sites at their promoter regions. This
is a likely link between the activation of RAS by Wnt/β-catenin
during CKD.
Inflammation
Chronic inflammation is observed in patients with CKD and it
contributes to the CVD morbidity and mortality by accelerating
the vascular inflammation (50). Release of cytokines at the site of
injury recruits the activated immune cells, which further enhances
the inflammatory state by producing additional mediators (51).
CXCL12 is a chemokine that binds to the CXCR4/7 and has a
role in homing of stem and progenitor cells in the bone marrow
to the site of injury or into the circulation. CXCL12/CXCR4 axis
shows atheroprotective properties by mobilizing the endothelial
progenitor cells to the site of injury (52). Local production of
Ang II has been implicated in the pathophysiology of inflam-
mation (53). Ang II stimulates the production of proinflamma-
tory molecules like NF-κB by Toll-like receptor 4 in addition
to Ang III and Ang IV via AT1 and AT2 receptors (54, 55).
Ang II also upregulates the “vascular cellular adhesion molecule-
1” (VCAM), “intracellular adhesion molecule-1” (ICAM), and
NF-κB, and thereby mediates the production of chemokines like
monocyte chemoattractant protein-1 (MCP-1), which recruit the
immune cells (56). In mesangial cells, the expression of ETS-1
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FIGURE 1 | Overview of RAAS system under pathological conditions
(CKD, DM, and CVD). The green boxes represent the peptide
components of RAAS system, blue represents the enzymes involved,
orange represents the receptors, brown represents the downstream
molecules/effectors, violet boxes represent the presentation before the
disease, and red represents diseased state. Ang, angiotensin; ACE,
angiotensin converting enzyme; AT1R, angiotensin type 1 receptor; AT2R,
angiotensin type 2 receptor; AT4R, angiotensin type 4 receptor; Mrg D,
Mas-related G-protein coupled receptor membrane D; VIF, vasodilation
inducing factor; PLC, phospho lipase C; DAG, diacyl glycerol; IP3, inositol
triphosphate; PKC, protein kinase C; MR, mineralocorticoid receptor; PI3K,
phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinase; NOX,
NADPH oxidase; ROS, reactive oxygen species; MMPs, matrix
metalloproteinases; PAI-1, plasminogen activator inhibitor-1; CTGF,
connective tissue growth factor; TNF-α, tumor necrosis factor alpha; JNK,
c-Jun N-terminal kinases; IKK-β, inhibitor of nuclear factor-kappa-B
kinase; NOS, nitric oxide synthase; CVD, cardiovascular disease; CKD,
chronic kidney disease.
(E26 transformation-specific sequence), a key regulator of vas-
cular inflammation, is upregulated in the presence of Ang II
via ROS production by NADPH oxidase and it participates in
inflammation by recruiting T-cells and monocytes/macrophages
into the vessel walls (57). In CKD patients, the cytokines; IL-
6, IL-1β, and TNF-α are elevated causing the cardiovascular
outcomes (58–60). The TAM (Tyro 3, Axl, Mer) ligand-receptor
pathway is involved in the regulation of inflammatory processes.
This pathway is deregulated in CKD patients and plays a role
in atherosclerosis and thrombosis (50). TAM ligands (Gas-6 and
Protein S) and receptors are expressed by the innate immune cells
that limit the production of proinflammatory cytokines, which
are stimulated through toll-like receptors (TLR) by the activa-
tion of suppressor of cytokine signaling (SOCS) (61, 62). TAM
ligand–receptor signaling is linked to the elevation of cytokines
in CKD patients, endotoxemia-mediated TLR activation, chronic
monocyte activation, and the involvement of macrophages in
atherosclerosis inCKD (50). ROS formation and activation of TLR
increases the expression of Gas-6 and shedding of TAM (sTAM)
receptors from monocytes binding to Gas-6, which results in the
deregulation of TAM receptor signaling, the cytokine, and TLR
cascades getting activated in CKD patients and finally chronic
inflammation (50). Due to over nutrition and lowphysical activity,
the cells are overloaded with glucose and free fatty acids (FFA),
the β cells are unable to produce more insulin, and this causes
insulin resistance leading to impaired glucose tolerance (63). The
cell avoids citric acid cycle when the caloric intake ismore than the
required energetics. Acetyl-CoA formed by oxidation of glucose
or FFA, combines with oxaloacetate to form citrate, which enters
the citric acid cycle, generating an excess amount of NADH that
impairs the electron transport in mitochondria resulting in the
formation of ROS. The cell avoids it by inhibiting the entry of fatty
acids into mitochondria as a result FFA build up in the cytosol
(64). Furthermore, the increase in intracellular FFA leads to a
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decrease in the transportation of GLUT4 to the plasmamembrane
and therefore the buildup of glucose concentration in the blood
(65). Constant exposure to glucose leads to dysfunctioning of
β cells and endothelial cells (66). In hyperglycemic conditions,
the endothelial cell metabolism is modified and implicated in
endothelial dysfunction, e.g., presence of high glucose is acti-
vating the NADPH oxidase resulting in the increased produc-
tion of ROS and an increase in oxidative stress by reducing the
entry of glucose-6-phosphate into the pentose phosphate path-
way thereby reducing the NADPH formation (67, 68). Excess of
glucose activates the arginase uncoupling the endothelial nitric
oxide synthase (eNOS) resulting in the increase of superoxide
anion production. Increased levels of glucose also diverts to
polyol pathway where it is converted to sorbitol by utilizing the
NADPH, increasing the ROS production, and activating NF-κB
signaling pathway (69–71). Due to changes in the endothelial
metabolism, advanced glycation products (AGEs) are formed,
which crosslink the extracellular molecules, causing increased
vessel stiffness, resulting in vascular complications (72). The AGE
products bind to their receptors (RAGE) that are expressed on
the monocytes, endothelial cells, and smooth muscle cells. They
are involved in the increased expression of scavenger receptor
class A in macrophages, which results in the uptake of the oxi-
dized LDL leading to the formation of foam cells, a character-
istic feature of atherosclerosis (69). Cholesteryl fatty esters are
the main component of foam cells that induce cytotoxicity and
are involved in lesion development in atherosclerosis (73). The
late stages of macrophages release the lipid content and tissue
factors leading to the formation of pro-thrombotic core, resulting
in rupture of plaque, leading to blood clot and contributing to
myocardial infarction and stroke (73). AGE–RAGE interaction
with vascular smooth muscle cells (VSMCs) is involved in cell
proliferation calcification process and also activates the NF-κB
signaling pathway where it controls the expression of cytokines
(71). RAGE also acts as an adhesive receptor in the endothelial
cells, attracting the immune cells at the site of injury (74). Nitric
oxide (NO) is formed from the arginine by eNOS in endothelium
and is involved in vasodilation. Asymmetrical dimethyl arginine
(ADMA), an endogenous analog of arginine, which is elevated in
atherosclerotic patients competes to bind at the active site of eNOS
thereby decreasing the NO (75). ROS produced due to eNOS
uncoupling and NADPH oxidase activity triggers the expression
of adhesion molecules, transmigration of immune cells, VSMCs
proliferation and migration, endothelial apoptosis, and oxidation
of lipids (69). Oxidized LDL results in the mitochondrial DNA
damage and dysfunction in the endothelial cells, leading to high
production of ROS (76). Xu et al. (77) analyzed cohorts of elderly
adults and reported that a proinflammatory diet is associated with
the systemic inflammation and reduced kidney function.
Fibrosis
At the site of cell injury or tissue damage, the cells are replaced
by the same cell type or with fibrous tissue after the clearance
of the inflammatory response. The kidneys have an intrinsic
capacity to repair cell death by the de-differentiation and prolifer-
ation of tubular epithelial cells. Failure of these processes results
in fibrosis during infarction/ischemia or toxic insult (78, 79).
Renal fibrosis is a prominent feature of every stage of CKD
where an excessive accumulation and deposition of ECM are
observed. At the beginning of inflammatory response in inter-
stitium, infiltrates of macrophage population can be observed,
which links inversely with the kidney function (80), that could
be either deleterious (M1 macrophages) or advantageous (M2
macrophages). This is followed by transdifferentiation of intersti-
tial cell population to myofibroblasts. These myofibroblasts have
characteristics of both smooth muscle cells and fibroblast cells,
which produce ECM proteins, like collagen or fibronectin, that
eventually results in scar formation (81, 82). Myofibroblasts are
the primary effector cells involved in both tissue remodeling and
fibrosis (83). They are mainly derived from the de-differentiation
of resident pericytes and fibroblast cells in the presence of fibro-
genic factors that promote cell to cell interaction. These fibro-
genic factors are secreted by endothelial cells, epithelial cells,
andmyeloid leukocytes especially the monocyte-derived cells and
they are also dependent on the environmental stimuli like hyper-
glycemia and hypoxia (84, 85). The M1 and M2 macrophages are
derived from monocytes based on the local stimuli. For exam-
ple, interferon gamma (IFN γ), TLR, tumor necrosis factor, and
granulocyte-macrophage colony-stimulating factor stimulate M1
macrophages. M1 macrophages are involved in tissue injury that
secretes proinflammatory cytokines such as IL-12, IL-23, IL-1, IL-
6, type-I interferon, and also produce reactive oxygen intermedi-
ates and nitric oxide. M2 macrophages, on the other hand, play a
role in tissue repair and are stimulated by IL-4, IL-10, IL-13, corti-
costeroids, vitamin D, macrophage colony-stimulating factor, and
TGF β (82, 86). Tubular epithelium is involved in the production
of ROS and inflammatory mediators that evade the interstitium
via basolateral secretion or paracrine pathways (82). They secrete
mediators like monocyte chemoattractant protein-1 (MCP-1), IL-
8, fractalkine, TGF β, endothelin by triggering megalin receptor-
mediated protein endocytosis during protein overload. They also
activate specific pathways with other co-receptors, cubilin and
amnionless, leading to interstitial inflammation, fibrosis, and loss
of nephron (87).
TGF-b1
The cytokine TGF-β1 is a prominent and powerful factor mediat-
ing myofibroblast activation, which integrates the effects of other
fibrogenic factors (88). TGF-β1 is synthesized by all types of
cells in the kidney and released in association with the latency-
associated peptide (LAP) binding to latent TGF-β-binding pro-
tein (LTBP). Upon stress stimuli like hypoxia (89), RAAS (90),
oxidative stress (91), and TGF-β1 are activated, binding to the
Type-II TGF-β receptor. Type II TGF-β receptor is a kinase
that recruits Type-I TGF-β and phosphorylates the downstream
molecules like Smad2/3, which in turn forms a complex with
Smad4 and then translocate to the nucleus to transcribe the
target genes along with other factors (88, 92). TGF-β1 shows
profibrotic effects on kidney through differentmechanisms where
it induces the production of ECM through Smad3 by binding
to the promoter region of collagen or Smad-independent path-
ways. This leads to an inhibition of its degradation by induc-
ing tissue inhibitor of metalloproteinase (TIMPs) and inhibiting
matrix metalloproteinases (MMPs). TGF-β1 is also involved in
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transdifferentiation of different types of kidney cells to myofi-
broblast cells (88, 93, 94). It has a role in podocytopenia where
the podocytes undergo apoptosis and detach from the glomeru-
lar basement membrane resulting in the loss of integrity of
microvasculature (95). In hyperglycemic conditions, the AGEs
and Ang II induce transdifferentiation of epithelial to mesenchy-
mal transition (EMT) mediated through Smad3 phosphoryla-
tion (96, 97). TGF-β1 stimulates the differentiation of epithe-
lial, endothelial, and macrophage cells to mesenchymal transi-
tion synthesizing ECM (81, 98). Stimulation of myofibroblast
with TGF-β1 increases the expression of cannabinoid receptor 1
that increases collagen expression (99). The latent form of TGF-
β1 is protective against inflammation and fibrosis by phospho-
rylating Smad7 (inhibitory Smad) (100). TGF-β1 shows effects
via Smad-independent pathways like p38, JNK, extracellular-
signal-regulated kinase (ERK), mitogen-activated protein kinase
(MAPK), integrin-like kinase (ILK) PI3K/Akt (101–103). TGF-
β activates PI3K that phosphorylates Akt and is involved in
fibroblast proliferation and ECM deposition (92). Inhibition of
PI3K activity results in a decrease in TGF-β-Smad2 phospho-
rylation and has an effect on EMT and cell migration (104). In
mesangial cells, TGF-β1 activates phosphatidylinositol 3-kinase
PI3K/Akt signaling, resulting in the mesangial cell hypertrophy
and fibrosis in diabetes (105, 106). High glucose levels, protein
glycation end-products, Ang II, endothelin-1, and growth factors
like PDGF and EGF, induce cell proliferation through PI3K/Akt
signal transduction (92).
Upregulation of renin and angiotensinogen was observed in
glomeruli and involved in the renal scarring or repair by the
action of Ang II (107). Transfection of glomeruli with renin and
angiotensinogen stimulates the proliferation of fibroblast cells,
increases the production of ECM (by inducing the mRNA of
proteins like type I procollagen and fibronectin in culturedmesan-
gial cells) and also transcribes collagen type 1 (IV) and 3 (IV)
but not type I in cultured proximal tubular cells by Ang II which
in turn depends on TGF-β expression (107). Renin alone is able
to stimulate the expression of TGF-β in mesangial cells and this
could contribute to renal fibrosis despite of Ang II blockade (108).
Expression of “connective tissue growth factor” (CTGF), a fibrotic
mediator is increased in the kidney induced by TGF-β and Ang
II (109). Ang II induces the “plasminogen activator inhibitor-
1” (PAI-1) and “tissue inhibitor of matrix metalloproteinases-1”
(TIMP-1) via AT1R, which inhibits metalloproteinase affecting
the matrix turnover, resulting in accumulation of ECM. PAI-1 is
also stimulated by Ang IV via AT4R in proximal tubules thereby
playing a role in renal fibrosis (110). In DN, Ang IV is formed by
the degradation ofAng IIwhen in high concentrations by different
enzymes and this induces PAI-I (111). Most of the fibroblast cells
in the interstitium originate from tubular epithelial cells through
a process called EMT. This process is mediated by TGF-β and
the fibroblast cells are involved in interstitial fibrosis and tubular
atrophy (112). Figure 2 shows the cells and themediators involved
in the fibrosis.
All these factors line up, and as a result the kidney loses its
function and faces oxidative stress, subsequently leading to the
accumulation of toxic substrates. Some of these substrates are
involved in the post-translational modification of proteins like
carbamylation and oxidation of LDL and HDL, which aggravate
the progression of atherosclerosis thus leading to CVD (113, 114).
RAAS blockade has been shown to be effective for the treatment of
CKD, CVD, DM, hypertension with proteinuria. With an increase
in the plasma aldosterone concentrations, the left ventricular
FIGURE 2 | Schematic representation of cellular mediators involved in renal fibrosis. The infiltration of macrophages secretes a set of mediators at the
injured sites of kidney resulting in the transition of resident cells to myofibroblast cells, which proliferate and secrete the extracellular matrix compounds.
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mass has shown to be larger in early CKD stages in hypertensive
patients (115).
Uremic Toxins
Uremic toxins are in general the waste products that accumulate
in the body fluid due to dysfunction of the kidney. They are
divided into small water soluble compounds, middle molecules,
and protein-bound uremic compounds (116). Among protein-
bound uremic toxins, para-cresol sulfate (PCS) and indoxyl sulfate
(IS) are linked to the cardiovascular comorbidities (117). p-cresol,
a metabolite of p-cresol sulfate showed reduced contraction rates
of cardiomyocytes, resulting in the irregular beating mediated by
protein kinase C (PKC) by increasing the intracellular calcium
levels (118). Furthermore, p-cresol is involved in the increased
endothelial micro-particle shedding mediated by Rho-kinase in
hemodialysis patients, leading to endothelial dysfunction, which
is also observed in acute coronary syndromes, acute ischemic
stroke, and venous thromboembolism (119–122).
Indoxyl sulfate also contributes to atherosclerosis and periph-
eral artery diseases. Indoxy sulfate stimulates NADPH oxidase in
endothelial cells, increasing the ROS formation and decreasing
the levels of glutathione, thus elevating oxidative stress (123). The
uptake of IS through organic anion transporter 3 (OAT 3), further
stimulates the expression of “prorenin receptors” (PRR) in the
aorta of a CKDmousemodel, thereby activating aryl hydrocarbon
receptors (AhR) and NF-κ B in VSMCs. Activation of PRR by IS
promotes cell proliferation and expression of tissue factors like
platelet-derived growth factor and receptor (PDGF/R) in VSMCs.
It also activatesMAPKpathways, thus linking the uremia-induced
cardiovascular events (124, 125). Moreover, IS stimulates the pro-
duction of IL-1, IL-6, and TNF-α in THP-1 cells. Lekawanvijit
et al. (126) demonstrated that IS plays a critical role in cardiac
remodeling by acting as profibrotic, prohypertrophic, proinflam-
matory factor, mediated by the activation of MAPK (p38, p42/44)
and NF-κ B pathway. IS also upregulates the expression of ICAM
andMCP-1 through ROS production, activating NF-κ B pathway
in endothelial cells. PCS and IS stabilize the active form of epider-
mal growth factor (EGFR) and help in dimerization and phospho-
rylation, leading to an increase in the MMP2/9 expression either
directly or by its downstream molecules. Therefore, they are both
involved in renal tissue remodeling (127). Under oxidative stress,
the protein-bound uremic solutes have an impact on the cardiac
tissue architecture as well as on the kidney tissue. For example,
uridine adenosine tetraphosphate (Up4A), which is synthesized
by the endothelial cells acts via purinergic receptors P2Y that acti-
vatesMEK, ERK1/2 by phosphorylation, and regulates the expres-
sion of vascular calcification (VC) mediators like Cbfa, Msx2,
Osx, OCN, osteopontin (OPN) leading to the transdifferentiation
of vascular smooth vessel cells to osteochondrogenic cells (128,
129). In VSMCs, Up4A stimulates the production of ROS by Nox1
dependent way and increases the expression of MCP-1 through
phosphorylation ofMAPK via P2Y (2) receptor (130). The uremic
toxin phenyl acetic acid is associatedwith arterial vascular proper-
ties in patients with CKD that are undergoing hemodialysis (131).
It also inhibits the inducible nitric oxide synthase (iNOS) and
impairs the macrophage function, thus increasing the incidence
of infection in uremia (132, 133).
Vascular Calcification: A Link Between CKD, DM,
and CVD
The mechanism of VC is multifactorial and is poorly understood.
The unusual deposition of calcium is observed in media and
intima of the vessel, which changes the elasticity and the hemody-
namics of the vessel wall that result in stroke and ischemic heart
disease (134). This ectopic calcification is noticed in atheroscle-
rosis, diabetes, hypertension, dyslipidemia, and CKD (134). The
main presentations of calcification are atherosclerotic lesions,
medial calcification, aortic stenosis, and calciphylaxis, which are
the most dramatic and often fatal entity. Atherosclerosis, CKD,
hyperphosphatemia, and vitamin K-targeting oral anticoagulants
have emerged as key contributors to VC.
Vascular calcification is an active and highly regulated process,
closely resembling osteogenesis. The factors contributing to the
VC are the high levels of calcium and phosphorous due to abnor-
mal bone metabolism, transition of VSMCs to chondrocyte or
osteoblast-like cells, imbalance in the levels of inhibitors of cal-
cification, low levels of klotho expression, high levels of parathy-
roid hormone (PTH), and fibroblast growth factor-23 (FGF-23)
expression, Vitamin D, and ECM remodeling (135, 136). VC is
characterized by transdifferentiation of VSMCs to osteoblast-like
cells where they express a number of bone matrix proteins (137).
High plasma calcium phosphate product (CaP) contributes
to this active process and hyperphosphatemia is considered a
key driver of VC in CKD. VC is observed due to imbalance
between inhibitory and inducingmediators. Themost relevant are
OPN, osteoprotegerin (OPG), fibroblast growth factor-23 (FGF-
23), bone morphogenetic proteins (BMP), matrix-GLA protein
(MGP), CD73, aldosterone, fetuin, pyrophosphate, magnesium,
and uremic toxins like Up4A. Increased expression of OPN is an
indicator of VC and transformation of VSMC to osteoblast-like
cells (138). Unphosphorylated OPN enhances whereas phospho-
rylated OPN decreases VC (138). The amount of OPN can be
pharmacologically modified by Mg2+ (139, 140). OPG is a decoy
receptor for receptor activator of nuclear factor-kappaB ligand
(RANKL) that inhibits RANKL-induced VC and bone loss (141).
OPG /  mice display osteoporosis and VC. The phosphaturic
hormone FGF-23 activates the FGFR1 receptor in the presence
of Klotho (142). Klotho has FGF-23-independent phosphaturic
actions. However, it is still unclear whether FGF-23 or Klotho
exert direct effects on VSMC phenotype (143). Klotho-deficient
mice display accelerated aging, hyperphosphatemia, osteoporosis,
and VC. A human klotho mutation was associated with VC in a
teenager (144). Both, systemic inflammation and CKD decrease
Klotho expression. In CKD, FGF-23 levels increase more than a
100-fold in response to hyperphosphatemia, and elevated FGF-23
levels are predictive of cardiovascular events (145).
Bone morphogenetic proteins are crucial mediators of vascular
remodeling and neovascularization (146). BMPs regulate calci-
fication in mesenchymal progenitor cells for cartilage and bone
(147) and modify expression of osteoblast markers like alkaline
phosphatase in VSMC. The expression of BMPs is increased at
VC sites. In addition, BMP and osteoblast homeoprotein Msx2
signaling pathway promotes the differentiation of myofibroblasts
into the osteogenic pathway and enhancesVC. BMP7 is a calcifica-
tion inhibitor whereas BMP-2 promotes VC (148). Protein C and
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S deficit and therapy with vitamin K-targeting anticoagulants are
risk factors for calciphylaxis (calcific uremic arteriolopathy) (149).
Vitamin K-dependent factors, including proteins C and S, require
glutamic acid carboxylation to yield gamma carboxyglutamic
residues (Gla) for activation. MGP is a vitamin K2-dependent
calcification inhibitor. MGP /  mice die a few weeks after birth
from aortic rupture due to massive calcification. Vitamin K defi-
ciency has been linked to VC in in vitro and in vivomouse studies
(150). Warfarin, an anticoagulant decreases the active form of
MGP and increases VC in CKD rats while vitamin K increased
active MGP and prevented VC in warfarin-treated rats (151).
Aldosterone contributes to VC by activating PIT1-dependent
osteo-inductive signaling (152). α2-HS-glycoprotein/fetuin levels
are decreased in CKD and associate with VC. Uremic toxins,
such as IS, induce expression of osteoblast-specific proteins in
human VSMC and associate with aortic calcification in CKD,
whereas in hypertensive rats, it promotes aortic calcification (153).
Leukocyte activation evoked by CKD directly contributes to VC
and pyrophosphate acts as an inhibitor of VC (154). A low extra-
cellular pyrophosphate level induces VC in murine model of
progeria (155).
Recently, protective effects of VC by magnesium through mul-
tiple mechanisms by decreasing the intimal media thickness and
aortic pulse wave velocity were described (139). In CKD rats,
treatmentwith amagnesium-based phosphate binder significantly
reduced aortic calcification compared to sevelamer-treated rats
(156). However, randomized controlled studies should address the
impact of magnesium administration in CKD patients.
Metabolic Derangements in CKD Modulating VC
In CKD, hyperphosphatemia, iatrogenic hypercalcemia, abnor-
mal levels of PTH and FGF/23, diabetes, and inflammation may
contribute to VC.
Hyperphosphatemia
High serum phosphate is associated to progression of VC and
increased cardiovascular risks in patients with CKD and in dial-
ysis. In the general population, serum phosphorus in the high
normal range is associated with increased mortality (157). Expo-
sure of VSMCs to high phosphorus concentrations results in loss
of smooth muscle proteins and differentiation into osteogenic
cells (158). Osteogenic transdifferentiation may end up in cell
apoptosis with production of apoptotic bodies acting as nucleation
sites for mineral deposition (159). Hyperphosphatemia-induced
nanocrystals upregulate the expression of BMP-2 andOPNVSMC
(160). Phosphorus binders are used to reduce phosphorus lev-
els as a key factor in the management of CKD-MBD (mineral
and bone disorder). The use of calcium-containing phosphate
binders that induce positive calcium balance is associated with
increased arterial calcification in themajority of studies (161). The
amount of calcium binders required to control phosphate results
in positive calcium balance (162) and most studies reveal that
the progression of VC is slower with non-calcium-based binders
as compared with calcium-containing binders. Excessive load of
calcium may favor the development of VC directly or through
an inhibition in PTH secretion with the consequent reduction of
bone turnover.
Hypercalcemia
In CKDpatients, hypercalcemia is usually a consequence of excess
calcium administration or vitamin D overdosing and is associated
to VC. High-calciummedium increases VSMC calcification (159)
and potentiates the effect of phosphate. Calcium induces the
release of matrix vesicles by VSMC that become calcified in the
absence of MGP (163).
Hypermagnesemia
In dialysis patients, high serum magnesium concentration was
associated with less VC. Low serum magnesium was associated
with increased mortality of hemodialysis and non-dialysis CKD
patients in observational studies (164). Magnesium-containing
phosphate binder-induced positive calcium balance is associated
with increased arterial calcification in the majority of studies
(165).Many interventional studies showed thatmagnesium-based
compounds aremore effective in reducing the phosphate level that
improve the survival and progression of VC (166).
Vitamin D
Vitamin D may have dose-dependent opposing effects on VC.
Vitamin D3 increases calcium transport into the cells and upreg-
ulates calcification-enhancing genes, osteocalcin, osterix, and
Runx2 (167). Protective effects of Vitamin D3 on VC may be
expected by its re-differentiating and anti-inflammatory proper-
ties (inhibition of TGFbeta and IL-6) (168), aswell as by increasing
the expression of VC inhibitors (MGP and Osteopontin).
Experimental studies in vitro and in vivo have shown that high
doses of calcitriol may induce VC (169, 170). Knockout mouse
models of FGF-23 and Klotho, which exhibit increased arterial
calcification, have elevated calcitriol levels (171). In mice, defi-
ciency in both FGF23 and renal 1-alpha-hydroxylase appear to
blunt arterial calcification (171). The effect of calcitriol on VC is
mainly due to the increase in phosphate absorption that in renal
failure results in hyperphosphatemia.
FGF-23-klotho
The hormone fibroblast growth factor-23 (FGF-23) induces phos-
phaturia and inhibits calcitriol synthesis and PTH production.
Serum levels of FGF-23 increase early in the development of CKD.
Several clinical studies demonstrated associations between higher
levels of FGF23 and VC (172). However, neutralization of FGF-
23 in uremic rats results in increased VC (173). A more recent
human study including a large population showed that FGF-23 is
not associated with VC (174). Some authors have not been able to
identify klotho, co-receptor for FGF-23 in human arteries (174).
Whether FGF23 has a direct effect on VC is still under debate.
Parathyroid hormone
Hyperparathyroidism is amajor risk factor formedial calcification
in renal disease (175). In uremic animals, PTH infusion produced
osteogenic transdifferentiation of VSMCs with increased calcium
deposition regardless of phosphate intake. The severity of medial
calcium deposition in the aorta correlates with the levels of serum
PTH in uremic rats with ovariectomy and with the loss of cortical
bone. High and low PTH is associated with high turnover and
adynamic bone disease, respectively. They both lead to decreased
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bone formation, a situations in which the bone is not efficient in
incorporating excess calcium and phosphorus (176). This may in
turn increase the risk for soft-tissue calcifications.
Diabetes mellitus
In diabetic patients, VC is commonly seen in coronary and vas-
cular arteries of lower limbs (177, 178). Monckeberg already
described medial artery calcification in an autopsy series that
was identified in older age, renal failure, and diabetes as the
factors associated with calcifications (179). In patient with dia-
betes, increased serum creatinine concentration, older age, and
poor glucose control are associated with VC and mortality. High
cholesterol levels, smoking, and body mass index were not asso-
ciated with increased VCs. In the Ldlr /  diabetic mice, a high
fat diet produces aortic calcification with concomitant upregula-
tion of osteogenic gene expression (180). Incubation of bovine
VSMCs with high glucose led to osteogenic transdifferentiation
and calcification (181). In diabetic arteriosclerosis, Msx1 and
Msx2 promote vascular mineralization (182). Furthermore, ele-
vation of glucose levels increased the BMP-2/Msx2-Wnt path-
way, which promoted osteogenic differentiation (181). Thus, it is
likely that high glucose may have direct effects on the osteogenic
differentiation of VSMCs and per se VC formation.
Dyslipidemia
From clinical studies, lipids do not appear to play a major role
on VC formation. In vitro, HDL inhibits the osteogenic differen-
tiation; among the fatty acids, stearate, promoted mineralization,
whereas inhibition of acetyl-CoA carboxylase reduced mineral-
ization (183). As mentioned above, in diabetes, cells are loaded
with FFAs. One of the abundantly found long-chain saturated fatty
acid is palmitic acid, induces the expression of BMP-2, Msx2,
and OPN in human aortic smooth cells through the expression
of long chain acyl-coA synthetase 3 and NF-κB that resulted in
osteoblastic differentiation (184). Oxidized lipids are involved in
VC. Oxidized LDL promotes the calcification process in human
coronary artery smooth muscle cells by upregulating the expres-
sion of mineral matrix proteins like osterix (Osx) and Runx2
mediated through nuclear factor of activated T cells (185, 186).
Inflammation-oxidative stress
Inflammatory cytokines and oxidative stress promote VSMC
expression of osteogenic transcription factors. In a murine
model of uremia, phenotypic changes in VSMCs occur prior
to calcium deposition, accompanied by elastin degradation,
possibly due to upregulation of proteases, including matrix
metalloproteinases (187).
Oxidative stress and oxidized lipids induce osteochondrogenic
differentiation of vascular cells in vitro. Oxidative stress induces
Cbfa1/Runx2 expression through modulation of PI3-kinase/Akt
signaling (188). In vitro studies show that TNF-α induces calcifi-
cation in VSMC. TNF-α promotes phosphate-induced calcifica-
tion by reducing efflux of a calcification inhibitor, pyrophosphate,
and its transport protein, ankylosis protein homolog (189). The
important role of oxidant stress on VC is demonstrated in exper-
iments showing that antioxidants block vascular cell calcification
in vitro.
Clinical Link of the Diseases
Epidemiological studies have so far confirmed and reported
that there is an association between CKD and CVD (190). Go
FIGURE 3 | Schematic representation of clinical link between chronic kidney disease, diabetes mellitus, and cardiovascular disease.
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et al. (191) conducted a study on the relationship between GFR
and cardiovascular events in a large groupwho had not undergone
dialysis or transplantation and demonstrated an inverse relation-
ship. The key mechanisms accounting for cardiovascular events
apart from the traditional risk factors could be disturbances in
mineral metabolism, anemia, ADMA (asymmetric omega NG,
NG-dimethylarginine), inflammation, and oxidative stress, which
are observed even in CKD. Whether CKD causes CVD or acts as
a marker is still controversial (192). Due to disturbances in the
metabolism in diabetes, themost effected cells are endothelial and
β cells. Since the micro and macro vessels are lined with endothe-
lial cells, the whole vascular system is damaged leading to CKD
and CVD. Therefore, disturbance in one of these diseases will
affect the other. Figure 3 shows how these diseases are interlinked
with each other in a clinical perspective.
Conclusion
The heart, kidney, and the vascular system are strongly related
and help in maintaining hemostasis and cardiorenal equilibrium.
Unfavorable outcomes aremost common in CKD and for that rea-
son it may deserve a specific approach to evaluate its progression.
Due to the advancements in the basic research, many mechanistic
pathways have been elucidated in the context of these diseases
recently but none of the pathway could interpret the genesis of
CKD. Therefore, a key factor in intervention for CKD patients
is having an insight on the mechanisms of risk factors associ-
ated with it. Our knowledge about the underlying mechanism is
increasing, but obviously still at its infancy. However, knowing
the key components involved in the pathology of the diseases,
their pathophysiological significance and their trend during acute
phases, is essential as the basis for new prevention and treatment
strategies to combat these diseases in the future.
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